BioMarin Eyed for 47% Upside with $84–$88 Targets; Q4 Sales at $829.7M
Analysts assign BioMarin a median one-year target of $88.29 (47% upside) with 10 Buy and 5 Hold ratings; Piper Sandler keeps an Overweight rating but cuts its target to $84 from $122. Q4 consensus sales $829.7 million and EPS $0.25, as Voxzogo’s US and EU infant dwarfism label expansions drive growth.
1. Analyst Ratings Overview
Fifteen analysts covering BioMarin hold 10 Buy and 5 Hold ratings, with a median one-year price target of $88.29, implying 47% upside. On February 6, Piper Sandler reiterated an Overweight rating but reduced its target from $122 to $84.
2. Q4 Consensus Estimates
For the fourth quarter, consensus sales are pegged at $829.7 million and earnings per share at $0.25. These estimates reflect expectations set by analysts ahead of BioMarin's reporting, providing a baseline for performance evaluation.
3. Voxzogo Label Expansion
BioMarin's growth is driven by strong demand for its dwarfism therapy Voxzogo, aided by recent label expansions in both the United States and Europe for infant use, which are expected to further bolster revenue in upcoming quarters.